HOSPITAL UNIVERSITARIO RUBER
Departamento
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (14)
2023
-
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
The Lancet Child and Adolescent Health, Vol. 7, Núm. 3, pp. 180-189
-
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
Journal of the Pediatric Infectious Diseases Society, Vol. 12, Núm. 8, pp. 477-480
-
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
Future oncology (London, England), Vol. 19, Núm. 35, pp. 2349-2359
2022
-
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Clinical Cancer Research, Vol. 28, Núm. 20, pp. 4536-4550
-
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity
New England Journal of Medicine
-
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
New England Journal of Medicine, Vol. 386, Núm. 12, pp. 1142-1154
2021
-
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
npj Breast Cancer, Vol. 7, Núm. 1
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial
Journal of Clinical Oncology
-
Reimagining global oncology clinical trials for the postpandemic era: A call to arms
JCO Global Oncology, pp. 1357-1362
2019
2018
-
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
EMBO Molecular Medicine, Vol. 10, Núm. 12
-
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210
2016
-
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
Cell, Vol. 167, Núm. 1, pp. 260-274.e22